Best for Longevity
Best NMN for Longevity
Top 25 products ranked · Reviewed May 2026 · 250–1000 mg clinical dose
Why NMN for Longevity
NMN plays a supporting role in longevity. NMN is a direct precursor to NAD+ (nicotinamide adenine dinucleotide), a coenzyme critical for energy metabolism, DNA repair, and sirtuin activation. Not to be confused with niacin (vitamin B3) or nicotinamide riboside (NR), which are separate NAD+ precursors.
What dose to look for
Clinical studies typically use 250–1000 mg of nmn. Most human studies use 250–1000 mg/day. 500 mg is the most common supplemental dose. Higher doses (up to 1200 mg) have been used in clinical trials. Products below this range may not deliver meaningful results.
What the research says
NMN has moderate clinical evidence for longevity benefits. Growing body of human trials on NAD+ levels, but long-term health outcomes are still emerging Learn more
Clinical research on NMN (Nicotinamide Mononucleotide)
MODERATE — human evidence is biomarker RCTs only (reproducible blood NAD+ elevation); no human longevity, senescence, or mitochondrial-outcome trials · 250–500 mg/day (clinical-trial range 100–1,200 mg/day)
- •Multiple short-term RCTs (Irie 2020, Yoshino 2021, Igarashi 2022, Pencina 2023, Yi 2023) consistently raise whole-blood NAD+ and NAD+ metabolites in a dose-dependent way — the single most reproducible human NMN finding. This is a target-engagement biomarker (proof the molecule reaches its pathway), not evidence of a downstream cellular-aging benefit. PubMed
- •Pencina 2023 RCT of pharmaceutical-grade microcrystalline NMN (MIB-626) in overweight/obese adults aged 45+ substantially raised circulating NAD+ and its metabolites and was well-tolerated. It is a physiologic/biomarker trial with no hard cellular, senescence, or longevity outcome, and it is sponsor-funded by Metro Biotech. Secondary metabolic signals (body weight, LDL, diastolic BP) appeared but were not the point — the reproducible result is NAD+ elevation, not clinical benefit. PubMed
- •No human RCT has shown NMN extends lifespan, healthspan, or any senescence/mortality endpoint. The 'reverses aging' framing rests on rodent data — most prominently Mills 2016, which improved several mouse healthspan markers but did NOT produce statistically significant lifespan extension in the C57BL/6N strain despite how it is popularly cited.
- •The nearest human 'aging' signal — a blood-based 'biological age' estimate that shifted on NMN in the Yi 2023 dose-ranging RCT (n=80) — is exploratory and not a validated longevity surrogate. Nearly all positive human trials are small (n=10–108), 8–24 weeks, industry-funded, and often share a single NMN supplier, so the effective independent evidence base is thinner than the trial count suggests.